Brazil Cell and Gene Therapy Market Size, Share, Trends and Forecast by Therapy Type, Indication, Delivery Mode, End User, and Region, 2026-2034

Brazil Cell and Gene Therapy Market Overview:

The Brazil cell and gene therapy market size reached USD 298.30 Million in 2025. The market is projected to reach USD 794.01 Million by 2034, exhibiting a growth rate (CAGR) of 11.49% during 2026-2034. Strategic alliances, increased funding for rare disease research, and the creation of national research institutions are driving the cell and gene therapy market. These efforts enhance local production, strengthen research capacity, promote technology transfer, ensure equitable access, thereby contributing to the expansion of the Brazil cell and gene therapy market share.

Brazil Cell and Gene Therapy Market Trends:

Strategic Collaborations Enhancing Access to Advanced Therapies

Collaborative partnerships among global biotech leaders, research organizations, and healthcare providers are greatly advancing the Brazil’s cell and gene therapy sector. These partnerships facilitate the exchange of technical knowledge, enhance clinical research capabilities, and create a dependable framework for the development of large-scale therapies. Collaborations with international organizations enable a transfer of knowledge, permitting Brazilian institutions to embrace advanced technologies in manufacturing, quality control, and clinical implementation. These efforts additionally improve the access to cutting-edge treatment options for patients, closing the divide between innovation and availability. The resulting ecosystem encourages workforce growth via targeted training initiatives and supports compliance with international regulatory and safety standards. Furthermore, global collaboration enhances clinical execution by linking local research networks with international therapeutic pathways, resulting in quicker approval and market launch schedules. These joint initiatives collectively broaden the scope of precision medicine and establish Brazil as a regional frontrunner in innovations related to cellular and genetic treatments. In line with this trend, in 2025, CTMC (Resilience & MD Anderson Cancer Center) partnered with Einstein Hospital Israelita in Brazil to launch the Global Cell Therapy Network Alliance, aiming to expand cell therapy access in Brazil and Latin America. The collaboration focuses on accelerating adoption and clinical implementation of advanced cellular therapies across the region.

Strengthened Investment in Rare Disease Research and Local Manufacturing

The increase in funding for rare disease research, along with programs supporting domestic production, is a significant factor impelling the Brazil cell and gene therapy market growth. Monetary support from international and local partners facilitates the creation of strong research and development (R&D) pipelines focused on creating therapies for diseases with few treatment alternatives. Through significant investment in clinical trials, infrastructure, and workforce education, these programs promote the development of sophisticated therapeutic platforms suited to Brazil's healthcare requirements. Technology transfer agreements also bolster local capabilities, facilitating domestic production that diminishes reliance on imported treatments and lowers costs. Incorporating these innovations into the public health system guarantees that advanced therapies reach a broader population segment. This convergence of scientific investment, local skill development, and fair healthcare access not only support market growth but also bolsters Brazil's status as a prominent biotechnology center in Latin America. Directly illustrating the significant investment in R&D and local production, GEMMABio partnered with Fiocruz in 2024 to fund and develop gene therapy treatments for rare diseases in Brazil with up to $100 million supporting research, clinical trials, and local manufacturing. The collaboration included technology transfer to enable local production and broader access through Brazil’s public health system (SUS). Initial programs targeted GM1 gangliosidosis, Krabbe Disease, Metachromatic leukodystrophy, and three additional therapies, aiming to make advanced treatments affordable nationwide.

Establishment of National Research Institutions Promoting Innovation

The establishment of specialized national institutes focused on cell and gene therapy research is fueling considerable progress in Brazil’s biotechnology industry by uniting scientific expertise, clinical capacity, and technological resources to accelerate the development and translation of advanced genetic treatments. Centralized organizations offer an organized system for teamwork among academic researchers, clinicians, and industry experts, guaranteeing effective alignment of scientific and clinical initiatives. By uniting knowledge and resources, these centers expedite the exploration, verification, and application of gene-based therapies into effective medical solutions. They further enhance the nation's innovation ecosystem by backing advanced training initiatives and developing a skilled workforce adept at managing intricate genetic technologies. Moreover, these institutions act as national reference centers for regulatory alignment, ethical supervision, and quality assurance, encouraging compliance with international standards. Their emphasis on precision medicine fosters the creation of targeted treatments for cancer and various genetic disorders, establishing Brazil as a leader in regional progress within genomic science. For instance, in 2025, Brazilian research groups launched the National Institute of Gene Therapy ‎‎(C2PO) to advance gene therapy research and applications. The institute aims to ‎centralize efforts in precision oncology and foster collaboration among scientists, ‎laboratories, and clinicians.It will focus on research, training, and education to accelerate ‎the development of innovative gene-based treatments in Brazil.‎

Brazil Cell and Gene Therapy Market Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the market, along with forecasts at the country and regional levels for 2026-2034. Our report has categorized the market based on therapy type, indication, delivery mode, and end user.

Therapy Type Insights:

• Cell Therapy
  • Stem Cell
    • Pluripotent Stem Cell
    • Cancer Stem Cell
    • Adult Stem Cell
  • Non-stem Cell
    • T-cell
    • Natural Killer Cell
    • Others
• Gene Therapy

The report has provided a detailed breakup and analysis of the market based on the therapy type. This includes cell therapy (stem cell (pluripotent stem cell, cancer stem cell, and adult stem cell) and non-stem cell (T-cell, natural killer cell, and others)) and gene therapy.

Indication Insights:

• Cardiovascular Disease
• Oncology Disorder
• Genetic Disorder
• Infectious Disease
• Neurological Disorder
• Others

A detailed breakup and analysis of the market based on the indication have also been provided in the report. This includes cardiovascular disease, oncology disorder, genetic disorder, infectious disease, neurological disorder, and others.

Delivery Mode Insights:

• In-vivo
• Ex-vivo

The report has provided a detailed breakup and analysis of the market based on the delivery mode. This includes in-vivo and ex-vivo.

End User Insights:

• Hospitals
• Cancer Care Centers
• Pharmaceuticals and Biotechnology Companies
• Others

A detailed breakup and analysis of the market based on the end user have also been provided in the report. This includes hospitals, cancer care centers, pharmaceuticals and biotechnology companies, and others.

Regional Insights:

• Southeast
• South
• Northeast
• North
• Central-West

The report has also provided a comprehensive analysis of all the major regional markets, which include Southeast, South, Northeast, North, and Central-West.

Competitive Landscape:

The market research report has also provided a comprehensive analysis of the competitive landscape. Competitive analysis such as market structure, key player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided.

Brazil Cell and Gene Therapy Market News:

• April 2025: Institut Curie awarded a Franco-Brazilian chair to the CellAction platform to accelerate CAR-T cell therapy research for rare lymphomas, promoting collaboration between France and Brazil. The project, led by Dr. Marion Alcantara, focuses on epigenetic reprogramming of CAR-T cells to improve their persistence and efficacy, with a Phase I/II clinical trial planned for 2026. CellAction centralizes expertise in cell and gene therapies, enabling rapid translation from research to clinical application, with annual scientific exchanges and joint doctoral scholarships.
• October 2024: Terumo Blood and Cell Technologies expanded automated cell and gene therapy manufacturing in Brazil, Colombia, and Mexico to improve efficiency, reduce costs, and increase patient access. The company’s technologies, including the Quantum Flex™ Cell Expansion System and FINIA™ Fill and Finish System, streamlined the production of cell therapies like CAR-T. This initiative supported Latin America’s growing demand for scalable, affordable therapies, particularly in countries with large public health systems.

Brazil Cell and Gene Therapy Market Report Coverage:

Key Questions Answered in This Report:

• How has the Brazil cell and gene therapy market performed so far and how will it perform in the coming years?
• What is the breakup of the Brazil cell and gene therapy market on the basis of therapy type?
• What is the breakup of the Brazil cell and gene therapy market on the basis of indication?
• What is the breakup of the Brazil cell and gene therapy market on the basis of delivery mode?
• What is the breakup of the Brazil cell and gene therapy market on the basis of end user?
• What is the breakup of the Brazil cell and gene therapy market on the basis of region?
• What are the various stages in the value chain of the Brazil cell and gene therapy market?
• What are the key driving factors and challenges in the Brazil cell and gene therapy market?
• What is the structure of the Brazil cell and gene therapy market and who are the key players?
• What is the degree of competition in the Brazil cell and gene therapy market?

Key Benefits for Stakeholders:

• IMARC's industry report offers a comprehensive quantitative analysis of various market segments, historical and current market trends, market forecasts, and dynamics of the Brazil cell and gene therapy market from 2020-2034.
• The research report provides the latest information on the market drivers, challenges, and opportunities in the Brazil cell and gene therapy market.
• Porter's five forces analysis assist stakeholders in assessing the impact of new entrants, competitive rivalry, supplier power, buyer power, and the threat of substitution. It helps stakeholders to analyze the level of competition within the Brazil cell and gene therapy industry and its attractiveness.
• Competitive landscape allows stakeholders to understand their competitive environment and provides an insight into the current positions of key players in the market.